NCT03499899 - A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2018

Primary Completion Date

February 27, 2020

Study Completion Date

November 24, 2021

Conditions

Triple-negative Breast Cancer

Interventions

DRUG

LAG525

LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first

DRUG

PDR001

Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525

DRUG

Carboplatin

Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed

Trial Locations (33)

652

Novartis Investigative Site, Saida

3000

Novartis Investigative Site, Melbourne

4000

Novartis Investigative Site, Liège

4102

Novartis Investigative Site, Wooloongabba

6009

Novartis Investigative Site, Nedlands

10002

Novartis Investigative Site, Taipei

11217

Novartis Investigative Site, Taipei

23563

Novartis Investigative Site, Lübeck

28034

Novartis Investigative Site, Madrid

41013

Novartis Investigative Site, Seville

72076

Novartis Investigative Site, Tübingen

72703

Highlands Oncology Group, Fayetteville

75231

Novartis Investigative Site, Paris

80131

Novartis Investigative Site, Napoli

85224

Ironwood Cancer and Research Centers, Chandler

90110

Novartis Investigative Site, Songkhla

91054

Novartis Investigative Site, Erlangen

166830

Novartis Investigative Site, El Achrafiyé

169610

Novartis Investigative Site, Singapore

6423906

Novartis Investigative Site, Tel Aviv

C1280AEB

Novartis Investigative Site, Caba

H3T 1E2

Novartis Investigative Site, Montreal

G1S 4L8

Novartis Investigative Site, Québec

H 1122

Novartis Investigative Site, Budapest

H-6720

Novartis Investigative Site, Szeged

466 8560

Novartis Investigative Site, Nagoya

467-8602

Novartis Investigative Site, Nagoya

241-8515

Novartis Investigative Site, Yokohama

105-8470

Novartis Investigative Site, Minato Ku

Unknown

Novartis Investigative Site, El Metn

Novartis Investigative Site, Taipei

05505

Novartis Investigative Site, Seoul

03080

Novartis Investigative Site, Seoul